Dec 18 (Reuters) - Cocrystal Pharma Inc COCP.O:
COCRYSTAL PHARMA RECEIVES IRB APPROVAL FROM EMORY UNIVERSITY SCHOOL OF MEDICINE FOR PHASE 1B HUMAN CHALLENGE STUDY WITH CDI-988 FOR PREVENTION AND TREATMENT OF NOROVIRUS
COCRYSTAL PHARMA INC - SUBJECT ENROLLMENT FOR STUDY EXPECTED TO BEGIN IN Q1 2026
Source text: ID:nGNXkBgFB
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com;))